Acurx Pharmaceuticals has <a href="https://www.prnewswire.com/news-releases/acurx-announces-results-of-its-pioneering-research-with-ibezapolstat-in-collaboration-with-leiden-university-medical-center-at-the-premier-international-c-difficile-symposium-302256562.html">released</a> promising trial results for its lead drug candidate, ibezapolstat, an antibiotic for difficult-to-treat bacterial infections. It was found to effectively target Gram-positive bacteria without causing cross resistance with other antibiotics — in other words, ibezapolstat may work where other antibiotics fail. Even though Acurx stock has almost halved since the start of the year, analysts are upbeat, seeing upside of about 500%.

Acurx reports positive trial results for new antibiotic

Shares of several small diagnostics companies surged on Monday, August 19, amid what is expected to be a "dramatic increase" in demand for their tests to detect the monkeypox virus, <a href="https://seekingalpha.com/news/4141679-mpox-test-makers-end-day-huge-gains-disease-spreads">noted</a> Seeking Alpha. The outbreak has spread beyond Africa, with the first case of the latest strain <a href="https://ru.euronews.com/health/2024/08/15/health-sweden-first-mpox-case">reported</a> in Sweden last week. Meanwhile, the World Health Organization (WHO) has <a href="https://news.un.org/ru/story/2024/08/1455271">announced</a> that it is urgently scaling up support to affected countries to contain the spread of the virus.